[Administration of anti-HER2 and satisfaction of patients treated for breast cancer]. / Administration des anti-HER2 et satisfaction des patients avec un cancer du sein.
Bull Cancer
; 111(5): 441-451, 2024 May.
Article
em Fr
| MEDLINE
| ID: mdl-38480056
ABSTRACT
INTRODUCTION:
Quality of life (QoL) and patient satisfaction are major concerns in oncology.METHODS:
The aim of this prospective observational study was to evaluate these parameters according to the mode of administration of anti-HER2 (subcutaneous [SC] versus intravenous [IV]), the place of administration (Home Hospitalization or HOD versus hospital) for patients supervised by an advanced practice nurse (APN).RESULTS:
Between January 2022 and June 2023, 32 patients were included. They were statistically more satisfied with subcutaneous management (P=0.0004), a result explained by the speed of administration (43.5%), comfort during administration (26%) even though some expressed pain on injection and felt less anxiety (26%). Management by the APN seems more appropriate when anti-HER2 drugs were administered in HOD. In HOD, patients perceived an overall improvement in their quality of life, appetite and cognitive abilities, with a reduction in fatigue, pain and depression (P<0.05). However, the rate of outsourcing to HOD remained too low (30.4%), as 56.3% of patients would have liked to be cared for in HOD if they had had the opportunity.CONCLUSION:
SC administration of anti-HER2 under the supervision of an APN has advantages for the patient, resulting in greatest satisfaction and improved patient QOL, preferably in HOD.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Qualidade de Vida
/
Neoplasias da Mama
/
Satisfação do Paciente
/
Receptor ErbB-2
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
Fr
Revista:
Bull Cancer
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
França